| Accession |
PRJCA023223 |
| Title |
A Phase I Clinical Study of GC012F Injection in RRMM |
| Relevance |
Medical |
| Data types |
Proteomic Data
|
| Organisms |
Homo sapiens
|
| Description |
This is a single-arm, non-randomized, open-label study to evaluate the safety and efficacy of GC012F injection in patients with Relapsed/Refractory multiple myeloma (RRMM).Approximately 6-9 eligible patients will be enrolled in 3 dose cohorts to evaluate the safety of GC012F injection. |
| Sample scope |
Synthetic |
| Release date |
2024-01-31 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| No funding support
|
|
|
|
|
|
| Submitter |
mingyue
xiang (mingyue.xiang@gracellbio.com)
|
| Organization |
Gracell Biotechnologies Inc |
| Submission date |
2024-01-26 |
